Poor cancer prognosis is related to TILs, which express both TIM-3 and PD-1 and therefore combination therapy with anti-TIM-3 and anti- PD-1 could contribute to more effective tumor inhibition [108]. This evidence concerns the gene PDCD1 and cancer.